Charting the Course: TB Alliance 2021 Annual Report

We live in an age of pandemics. In this year’s report, Charting the Course, we review how recent progress in the fight to end TB will shape the global TB response for the millions impacted by this disease. 
For the first time in a decade, the TB situation is getting worse, not better. 

New Treatments

TB Alliance’s ZeNix trial of the BPaL regimen (bedaquiline, pretomanid, and linezolid) in South Africa, Eastern Europe, and Russia sought to optimize a six-month, all-oral treatment regimen by assessing various dosing modifications of the linezolid component of BPaL. Presented at the 11th IAS Conference on HIV Science, the data demonstrate improvement in the safety and tolerability of the BPaL regimen with alterations in linezolid dosing. “The results of this study are very reassuring. With a reduction in the dose and/or duration of linezolid, we can still offer patients a high chance of cure in only six months,” said Dr. Francesca Conradie, principal investigator for the ZeNix clinical trial, as well as South Africa’s Clinical Access Program for the regimen.

Reaching Those in Need

To date, 15 countries or regulatory bodies have approved pretomanid as part of the BPaL regimen for the treatment of patients with highly drug-resistant forms of TB, and regulatory applications have been submitted to another 17 countries and counting by Viatris, one of TB Alliance’s commercialization partners. A further 11 countries are actively enrolling patients in operational research to continue gathering evidence and implementing the regimen in other regions. The evidence generated from the Nix-TB and ZeNix clinical trials, which is now being replicated through operational research programs such as LIFT-TB, underscores the potential of short, all-oral, BPaL-based regimens for patients with highly drug-resistant TB.

Transforming TB Treatment

TB Alliance advanced the development of new TB medicines while navigating the spread of COVID-19 by pivoting research projects from labs within and across borders. As a global product development partnership with relationships all around the world, TB Alliance worked closely with our partners and researchers to advance both early- and late-stage research.

  • Adding new projects in the Lead Optimization phase
  • Advancing TBAJ-587 to Phase 1
  • Completing the process chemistry effort for TBI-223
  • Publishing preclinical results on TBAJ-876 showing shorter and more effective treatment over bedaquiline
  • Finalizing and presenting results from the ZeNix Phase 3 trial

Visit the TB Alliance website here or subscribe to their newsletter.

Published in GI-Mail 03/2022 (English edition).

  • Do you already know our monthly newsletter GI-Mail with useful tips on postgraduate courses?
    Sign up here.
  • Are you looking for vacancies or new career challenges? Here you will find the latest vacancies and job offers.
  • Do you already know our monthly job-information GI-Jobs with current job offers for doctors, managers and nurses? Sign up here.
  • Are you interested in up to date postgraduate courses and CME? In our education database »medicine & health« you will find new education events from over 2300 organizers.




    Comments are closed.